- CTIBIOTECH has launched CTIBIOTECH USA in Philadelphia with a combined $27 million investment in operations and intellectual property assets.
- The new subsidiary will provide 3D bioprinted human tissue bioassays and New Approach Methods to North American pharmaceutical, biomedical, and dermatocosmetics markets.
CTIBIOTECH™ has launched its North American subsidiary, CTIBIOTECH USA™, during the SelectUSA Investment Summit in Washington, D.C. The expansion includes a combined $27 million investment, consisting of nearly $12 million for U.S. operations over the next five years and an additional $15 million in intellectual property assets.
The new subsidiary will operate from Philadelphia, Pennsylvania, within the life sciences hub referred to as “Cellicon Valley,” in association with BioLabs for Advanced Therapeutics. According to the company, CTIBIOTECH USA will provide proprietary human cell and tissue bioassays and New Approach Methods (NAMs) to pharmaceutical, biomedical, and dermatocosmetics markets in North America.
The company stated that domestic production of its 3D bioprinted human tissue models is intended to simplify procurement and support researchers working on predictive and personalized medicine. CTIBIOTECH’s technologies include microtumor and human skin models designed to support drug discovery and therapeutic testing.
“The launch of CTIBIOTECH USA™ marks a crucial step toward solving this global health challenge. By bringing our revolutionary 3D bioprinting technologies, such as our microtumor and human skin models, directly to North America, we are providing researchers with the highly predictive, human-derived biological assays they need to reliably test new therapies and advance personalized medicine.”
Professor Colin McGuckin, President and Chief Scientific Officer of CTIBIOTECH
The launch was supported through collaborations with U.S., French, and European organizations, including SelectUSA, the State of Pennsylvania, the City of Philadelphia, Business France, and BPI France. The company said the expansion strengthens its contract research, development, and manufacturing organization (CRDMO) presence in the North American market.
